Ampio Pharmaceuticals Inc (AMPE)

[TJG]

There will be a lot of folks doing the exact same thing...

There is one thing that can possible give us a boost in the PPS as we await this new Phase III trial.... Its the Covid aspect of their drug. For entire second half of 2020 and all of 2021 there were less then five pieces of information put out on the OAK aspect of the drug. The entire focus was on the Covid trials and how this it was going to be a game changer.... Then the new idiot took over and Covid was shelved and not a word as to what was going on with it for months... then on the last earnings call he said they were going to evaluate the data.

If the company can show us any positive results from the trials and possible give us an update on how the drug could be expanded to help other raspatory ailments besides Covid that could send the PPS back up significantly from its current .20 cent range.

Now mind you that would take a bit of intelligence to see that doing an update on the Covid side would indeed help us all... and frankly I dont think this CEO has enough of that, intelligence, to fill a thimble

[Limey42]

Only watching this now. I believe in the product and will dive back in at a later date. Good luck all.

[TJG]

Well josey,most likely there will be you, me and a couple others here but it will take some time for more to drift in... I anticipate the next drop will come when the Q is released sometime next ,month..... my biggest concern is a RS being done by this twit.

But since its going to take 18 to 24 months that is something that will happen in the future... doing it now would only result in the PPS being sold back down to under a buck again... my guess is about half way through the trial once it gets under way.

[joseytheoutlawwales]

I’m holding as well. Have 40,000 shares currently.

I think we’ll see lower prices, and I’ll be buying the dips.

I still believe the science will work, and future bursts upon positive trial progression; filing, cohorts, etc; will each provide some upward traction.

Regardless of trial outcome, I expect a trade-able move to $1.50 range at some point. And I will be holding my shares to capitalize on that move.

[TJG]

And the morons decided to do a call before the market opens and give the worst news possible. 18 to 24 months to conduct a new Phase III trial at a estimated cost of at least 15 million dollars. God only knows why this dip shit of a CEO did not pick 4:30 on Friday to do this call.... which he could have done and still be in compliance with full disclosure regulation... Give the investment community the weekend to digest it...Nope he does it pre market so we can have a complete collapse of the stock at the opening bell.

Going to be very quiet around here for the next year and a half I would imagen. I will hold not going to take a several thousand dollar loss. Hope for the best when they get this done... and that no other large Pharma company beats them to the finish line.

Good Luck Everyone.

[TJG]

Already a cluster cant get in to the call using the number they put in the PR... just getting a recording of Stay on the Line for the next Available Operator... Call started 7 minutes late... surprising, not really

[TJG]

Whats key here is the timing. In the past all calls have been held at 4:30 pm, after the market has closed.

Holding this call at 8 am prior to the market open could be an indicator that they feel what they have to say could move the stock when the bell rings. If I had news that was mediocre I would not want it put out before trading started. All that would accomplish is to continue the beat down our share price is already experiencing.

We shall see

[Limey42]

Will be interested to see the contents of this call.

[TJG]

I will be on that call, and hopefully they have a plan in place that will get thig going in the right direction. If you missed it here is the call in formation


Toll Free dial-in number:

1 [phone]

Local dial-in number:

1 [phone]

Conference ID:

5564580

[drkazmd65]

Yeah - that was amazingly dumb.

the Company should have sought FDA's agreement on these changes prior to analyzing and unblinding the data

My only real question - in whether they can salvage these data in some way to please the FDA - by hiring some independent CRO or Statistical Consultant group to give them the raw data, blinded again to that new CRO, and have them redo the analyses from scratch.

If possible (and it may not be in the FDA's playbook) - it would be less expensive that having to redo the entire clinical trial.

Ughh,..

[TJG]

I could not agree more, the fact that there is only one other option out there for anyone suffering from joint pain in the knee or shoulder or elbow and that is a cortisone shot. The medical community is screaming for something better, yet this fool is wide open in the end zone and drops the pass.

The key part of the news release is this paragraph.. and for this idiot to not have done it is unthinkable. We all, as share holders were told by him that they were in constant contact with the FDA...well apparently they weren't.

FDA responded that it did not agree with the Company's proposed change from the ITT population to the mITT population for the primary endpoint analysis, that mITT is a substantive and material change to the Protocol and Statistical Analysis Plan that is not in accordance with the Special Protocol Assessment agreement, and that despite the COVID related impact on patients and trial centers, the Company should have sought FDA's agreement on these changes prior to analyzing and unblinding the data

[joseytheoutlawwales]

What baffles me is that from several insiders of AMPE this was essentially as close to a sure thing as one can find in startup biopharm.

It took only one special-needs stand-in CEO to literally screw the pooch.

[joseytheoutlawwales]

Not bad action today. Hopefully the sell off overdone and support has been found.

[TJG]

According to the bafoon running this he stated when he was on the call that they were in constant communication with the FDA as did the President of the company... and that unblinding it was in our best interest because they did not feel the FDA would require more data... that seems like a load of BS now...

As for funds I think they will indeed need more.. none of what they have told us about having cash on hand did not mention anything about funding another Phase III trial for OAK... so something has to give... and I doubt it will be any of the salary for the new board members or for the President, CFO and CEO so that leaves shareholders having to take the brunt of the cost in the form of dilution.

[joseytheoutlawwales]

Added from .22 to .24, another 24500 shares.

I see this drop as way oversold. Granted, we need a new ceo, but the compound and science are still strong. We need more info on why the fDa has this position on the trial.

Having to repeat another puts us too far back, and likely in need of further dilution to fund the trial. Hopefully we can climb back to .50s before that dilution hits.

But I believe in what Ampion can do, so I remain a Bull.

[TJG]

I have added at the .21 and 22 range today and will keep a close eye on it... I dont see it going beyond .20 simply because there are to many holding above a dollar to not take advantage averaging way, way down.

[joseytheoutlawwales]

At this point, the “cut and run” will leave me too far in the red. As I believe in the fact that ampion will prove out, I’m going to buy as this falls. But I don’t think we’ve seen the bottom.

[TJG]

I have said from the day he took over this CEO was an idiot, the first time he spoke to the shareholders on a conference call it was him telling us about himself and how great he was.

Well who ever this idiot got to advise him on unblinding this is as big an idiot as he is. All of this time, over three months wasted on waiting could have been spent on doing the now upcoming Phase III trial. We are looking at Q1 of next year before they are ready to resubmit.

There are two ways to look at this, dump and run or continue to believe in the product itself and buy the cheap shares... but one must beware of the possible reverse split here.... the money they have will not last as long if they have to fund another trial.

So under this CEO we have the Covid drug seemingly a bust and the rush to un-blind the OAK data a major blunder... Wonder how he will spin this as it being anyone but his fault.

[Limey42]

Wow, what a cluster f#@k!

[420man]

Tomorrow will be a blood bath.. If not, you KNOW this shit is rigged more than normal!!

[TJG]

No the end of the second quarter is June 30 and they hoped to have an answer by then. But with no updates as to the status on them cleaning up the data from Covid and the FDA update on OAK we sit and spin in the thirty cent range. Here it is 2/3 of April gone and they cant get the Covid data ready, ready from a study that concluded in December. This guy is a screw up, we need Mike to return from his medical time off ASAP. But like everyone his health is and should be his most important priority.

[MattSav]

I thought they had said they would have an answer by the end of 2nd quarter... That would be in May correct?

[TJG]

Exactly I hate to think that I will be using this as a flipping stock but if its there may as well take advantage of it. I picked off some of the offerings in the thirty cent range yesterday.

[joseytheoutlawwales]

Agreed.
Faith in the science, but too many startup biotechs die on the vine due to mismanagement.

Holding.

May still buy more if we drift lower, to trade out on a return to .60’s.

[TJG]

What a sad state of affairs this is turned into... my biggest problem is the complete lack of communication from this idiot of a new CEO.... everyone holding this for any time longer then 3 weeks is in the red.... updating shareholders on the current status of the FDA should be a priority for this idiot

[turning stone]

TJG

I have a severe bone spere in the knee as well as arth. I am using a cbd roll on that believe it or not does help but the knee still remains painful. I look forward to AMPIO's drug when it is possibly approved. It would be nice if it would happen by the end of this year. It gives me something to look forward to as I am not a canidate for knee replacement for other medical reasons. If it does not get approved I will have to live with this bum knee.

[TJG]

You may want to do some reading on this... your post indicates that you have not... there is good news coming in the future, but its a ways off... read the last PR it will give you some idea of the time line. Even if the FDA approves their latest request this will not hit the market until 2023 most likely... doesnt mean there wont be good news and price increases but as far as your doctor prescribing it, thats a long way away.

[turning stone]

I would expect that since AMPE has made it into Phase 3 with their drug good news is on the way.

[turning stone]

I have a knee that is so sore I can't wait for this drug to be approved.

[MattSav]

Wonder how many people are just watching to see this hold until power hour.. Curious to see what happens

[TJG]

we have been averaging 841,000 shares traded a day for the past 10 days... right now before noon we have over 26,000,000

Old saying "Volume Precedes Price"

[drkazmd65]

Man - that's a hell of a lot of volume before 10:00 am.

[TJG]

Good question on the hold the movement or will she come back to earth

[joseytheoutlawwales]

Solid move, do we crash back or continue?

Always watching, just had this one on the back burner.

[MattSav]

Ummm without any question I'll accept 4.50 a share haha

[TJG]

Makes me wonder if this person who is giving them a price target of $4.50 has a source on who the strategic partner may be.... and if the announcement is coming sooner then later

[TJG]

From the MarketWatch web site

Ampio Pharmaceuticals started at buy with $4.50 stock price target at Alliance Global Partners
Mar. 24, 2022 at 7:18 a.m. ET by Tomi Kilgore

https://www.marketwatch.com/

[drkazmd65]

I would be 'nice' to see something concrete come out.

[TJG]

Just glad to see they are going to release on time... not expecting anything earth moving, but them not submitting a delay form for the filing is always good news.

[MattSav]

Short and sweet press release and a few days early... Could we get the approval this week? Please haha

[drkazmd65]

CVM is kind of in a slow spiral downwards while 'we' shareholders wait for the management to actually get something public started with the FDA. It's annoying - however, I have also been using this as an 'opportunity' to add shares at what I regard as a good price - assuming that the company doesn't fall flat on it's face stumbling through the FDA filing processes.

It's been pretty much radio silence from CVMs corporate front for a lot of months now. Hopefully that means they are quietly dotting the "I"s and crossing the "T"s & just plain getting the job done.

Much like AMPE - CVM have a potential product/drug that appears to have a useful and positive effect after completing the actual clinical testing. They both just need to get the next stage of the job done already.

[TJG]

Nice, CVM looks like they are for sure on the right path to being approved in the near future.

Good Luck on all your trades.

[drkazmd65]

Agreed and understood. I tend to buy speculative biotech/biomed stuff low and sit on it for a long time if necessary. That's my plan with AMPE as well. Am planning on adding some more shares next week when my next cash allocation in the trading account gets settled.

I've been sitting on a stash (and have added to it recently) of CVM for a bunch of years waiting for them to get their Phase III testing done, and their package submission to the FDA done. Phase III got done and data was read out last year - looks like there is a significant benefit to their cancer patients in at least one wing of their trial. Even after they get approval I may continue to hold part of that stash of CVM shares.

[TJG]

Just so people understand when they listen to this... AMPE is a long term hold... one example I can give is this, I was in NVAX years ago... they were going to develop a Bird Flu, if you dont know Bird Flu was going to be the pandemic that Covid turned out to be. It was selling for a couple of bucks and would bounce to $4 and then back down... Like any bio tech you have to be patient. NVAX is trading at $77 today... its 52 week high is $220. If you stick with these long enough you can at time make a very very good return. I of coarse did not stick with NVAX and took my greedy profit when it hit $6 a share.

https://www.reuters.com/article/us-novavax-shares/novavax-shares-jump-on-promising-bird-flu-vaccine-data-idUSBNG2239920070402

Thats why I am once again buying this down here now that they have at least gave us some honest information on how long we may be waiting.

Good Luck

[drkazmd65]

Good to know. Thanks for sharing the information.

They finally gave an update on the Covid aspect...

I'll make a point of listening to the presentation over the weekend.

[TJG]

If your a long term investor in Ampio the you must listen to the presentation. There is a lot of positive in this presentation and it is going to be very difficult for the FDA to not approve this for OAK. As Josey said last year, this company will reach it highest level based on OAK and that Covid was just icing on the cake. Covid has changed as have the treatments so when approved it will add to the bottom line but not in the way OAK will.

Buy at this level is in my personal opinion a gift that comes along only a few times a year. Again, you should listen to this presentation in its entirety.

https://ampiopharma.com/investors/presentations-media/

[TJG]

They finally gave an update on the Covid aspect... the data is being analyzed and will be announced by the end of Q 2. So its not a forgotten arm of the drug. Not sure why that was so difficult for them to release but we now know its still on the table.

[TJG]

That link did not open, this one is from their web page it may do the trick

https://ampiopharma.com/investors/presentations-media/

[HomerRomer]

This link should work for the CC replay with slide presentation.
https://event.on24.com/eventRegistration/console/EventConsoleApollo.jsp?&eventid=3574331&sessionid=1&username=&partnerref=&format=fhvideo1&mobile=&flashsupportedmobiledevice=&helpcenter=&key=964B6C5B80DB9EFD05CA55D0977BD0D5&newConsole=true&nxChe=true&newTabCon=true&consoleEarEventConsole=false&text_language_id=en&playerwidth=748&playerheight=526&eventuserid=517349847&contenttype=A&mediametricsessionid=448125962&mediametricid=5018984&usercd=517349847&mode=launch

[drkazmd65]

Yeah - nothing on there about the COVID applications that I see either. The OAK data does look fairly promising though.

The share price beat-down still continues though.